Identifying and validating blood mRNA biomarkers for acute and chronic insufficient sleep in humans:

a machine learning approach by Laing, Emma et al.
Submitted: 19 April, 2018; Revised: 29 June, 2018
© Sleep Research Society 2018. Published by Oxford University Press [on behalf of the Sleep Research Society].
1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Original Article
Identifying and validating blood mRNA biomarkers for 
acute and chronic insufficient sleep in humans: a machine 
learning approach
Emma E. Laing1,*, , Carla S. Möller-Levet2, Derk-Jan Dijk3 and  
Simon N. Archer3,*
1Department of Microbial Sciences, School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University 
of Surrey, Guildford, UK, 2Bioinformatics Core Facility, Faculty of Health and Medical Sciences, University of Surrey, 
Guildford, UK and 3Surrey Sleep Research Centre, School of Biosciences and Medicine, Faculty of Health and Medical 
Sciences, University of Surrey, Guildford, UK
*Corresponding authors. Emma E. Laing. Email: e.laing@surrey.ac.uk; Simon N. Archer. Email: simon.archer@surrey.ac.uk
Abstract
Acute and chronic insufficient sleep are associated with adverse health outcomes and risk of accidents. There is therefore a need for 
biomarkers to monitor sleep debt status. None are currently available. We applied elastic net and ridge regression to transcriptome samples 
collected in 36 healthy young adults during acute total sleep deprivation and following 1 week of either chronic insufficient (<6 hr) or 
sufficient sleep (~8.6 hr) to identify panels of mRNA biomarkers of sleep debt status. The size of identified panels ranged from 9 to 74 
biomarkers. Panel performance, assessed by leave-one-subject-out cross-validation and independent validation, varied between sleep debt 
conditions. Using between-subject assessments based on one blood sample, the accuracy of classifying “acute sleep loss” was 92%, but only 
57% for classifying “chronic sleep insufficiency.” A reasonable accuracy for classifying “chronic sleep insufficiency” could only be achieved by a 
within-subject comparison of blood samples. Biomarkers for sleep debt status showed little overlap with previously identified biomarkers for 
circadian phase. Biomarkers for acute and chronic sleep loss also showed little overlap but were associated with common functions related 
to the cellular stress response, such as heat shock protein activity, the unfolded protein response, protein ubiquitination and endoplasmic 
reticulum-associated protein degradation, and apoptosis. This characteristic response of whole blood to sleep loss can further aid our 
understanding of how sleep insufficiencies negatively affect health. Further development of these novel biomarkers for research and clinical 
practice requires validation in other protocols and age groups.
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Statement of Significance
Insufficient sleep poses a significant risk to physical and mental health, and the general safety of individuals. The development of an objec-
tive assessment is important for treatment and diagnosis, with applications in many real world situations, for example, suspected sleepy 
(drowsy) driver accidents, assessing “fitness for duty,” interpretation and diagnosis of sleep disorders, and evaluation of therapeutic sleep 
interventions. Here, we show that sets of blood mRNA transcripts, related to biological functions associated with cellular stress responses, 
can accurately predict acute sleep loss but detecting chronic sleep insufficiency is more challenging.
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Introduction
A multitude of recent epidemiological and interventional studies 
have established that insufficient sleep is associated with adverse 
health outcomes. Excessive sleepiness, impaired sustained atten-
tion, changes in mood, and a variety of adverse physical health 
outcomes such as obesity, diabetes, and cardiovascular disease, 
have all been demonstrated to be linked to insufficient sleep 
[1–4]. Indeed, it has been recommended that adults sleep 7 or 
more hours per night to avoid the adverse health outcomes asso-
ciated with sleep debt [5]. However, in most studies quantifica-
tion of sleep debt does not extend beyond subjective assessment. 
Objective assessment of sleep debt status will aid the develop-
ment of the next generation of epidemiological studies on the 
health consequences of insufficient sleep. Objective assessment 
of sleep debt status also has direct applications in many real 
world situations, for example, suspected sleepy (drowsy) driver 
accidents, assessing “fitness for duty,” diagnosis of sleep disor-
ders, and evaluation of therapeutic sleep interventions [4, 6, 7]. 
Yet, methods that can objectively assess sleep debt status and be 
deployed on a large scale are currently not available.
Experimental research approaches to identify putative bio-
markers for sleep debt status typically include laboratory stud-
ies of acute sleep deprivation and chronic sleep restriction. 
Acute total sleep deprivation consists of foregoing sleep and 
being awake for more than 24 hr, whereas chronic sleep restric-
tion can, for research purposes, be defined as getting some but 
insufficient (e.g. <6 hr) sleep during consecutive (e.g. 3 or more) 
24 hr periods [6]. Biomarker discovery can make use of univari-
ate and multivariate high-throughput data derived from sam-
ples (blood, saliva, urine, or specific tissues and/or organs [6, 8]) 
collected in these protocols. The transcriptomes of organs, such 
as the brain and liver, change in response to acute total sleep 
deprivation, and sleep displacement and disruption, as has been 
shown in animal studies [9–12]. In humans, biomarker discov-
ery has focused on samples from blood, saliva, or urine, because 
internal organs are not easily accessible. Early attempts to iden-
tify biomarkers for sleep debt in easily accessible sources such 
as saliva, were informed by transcriptomic studies, with one 
particular molecule, amylase, identified as a putative biomarker 
for acute total sleep loss in drosophila and humans. Levels of 
mRNA encoding amylase and amylase enzymatic activity were 
both elevated in the saliva of individuals who experienced 
acute total sleep deprivation [13]. Metabolomic approaches have 
identified changes in blood metabolites in response to chronic 
sleep restriction in rodents and humans. In a carefully con-
trolled study, the molecules oxalic acid and diacylglycerol 36:3 
were identified as putative cross-species biomarkers of chronic 
sleep debt [14]. However, these pioneering studies neither quan-
tified nor independently validated the ability of the putative 
biomarkers to monitor sleep debt at the level of the individual. 
Furthermore, these studies focused on univariate biomarkers 
and no attempts were made to identify a panel. A panel consist-
ing of multiple features is likely to be more sensitive and robust 
than an assessment based on a single feature [8]. Multivariate 
approaches have been shown to be successful in a number of 
areas including biomarkers for cancer and neurodegeneration 
[8].
Theoretical models predict [15], and experimental sleep 
studies have shown [16], that in humans sleep propensity is 
governed by two processes, sleep homeostasis and circadian 
rhythmicity. Identification of biomarkers of the status of these 
processes is pertinent to our understanding of sleep regulation. 
Recently, we have demonstrated that the blood transcriptome 
in one or two blood samples contains sufficient information to 
reliably predict the circadian phase of the master pacemaker 
in the human hypothalamus as indexed by the plasma mela-
tonin rhythm [17]. Here, we investigate whether a panel of blood 
transcriptome features can be used to predict the homeostatic 
aspect of sleep regulation, that is, sleep debt status.
The human blood transcriptome is affected by acute total 
sleep deprivation and chronic sleep restriction, as well as sleep 
timing and circadian phase [18–21]. This implies that the blood 
transcriptome is a potential source for identifying biomarkers 
associated with sleep debt variables with the provision that 
confounding factors such as circadian phase are adequately 
considered and taken into account. Our previously reported 
effects of total sleep deprivation and chronic sleep restriction 
[18] were based on time series of 10 transcriptome samples col-
lected across the circadian cycle in each participant and in two 
sleep debt conditions. Significant effects of sleep debt condi-
tion were assessed for individual transcripts at the group level, 
using a within participant comparison. Ideally a biomarker 
should not require many samples or a within participant com-
parison. Accordingly, here, we compare approaches to identify 
and validate multivariate blood transcriptome biomarker panels 
for assessing the acute and chronic sleep debt status of an indi-
vidual by using only a few samples, and compare the molecular 
characteristics of the panels.
Identifying a panel of mRNA biomarkers for a given condition 
of interest, for example, chronic insufficient sleep, represents 
a feature selection problem. There are different approaches to 
selecting features from large scale data; univariate filtering (i.e. 
application of prior knowledge, statistical, and/or correlation 
thresholds), multivariate wrapped (e.g. partial least-squares 
regression [17]), and/or embedded methods (e.g. LASSO [22] and 
elastic net [23] penalized regression techniques). We have previ-
ously shown that a priori knowledge-based filtering may not be 
the optimal approach for developing a predictive model of circa-
dian phase [17]. Nevertheless, prefiltering of features, before the 
application of multivariate wrapped/embedded methods, has 
been reported to be advantageous in some situations [24]. Here, 
we have therefore compared these different approaches in iden-
tifying biomarkers for sleep debt status. Validation is essential 
in evaluating biomarker performance. Although independent 
validation (IV) is the gold standard, validation methods such as 
leave-one-out or k-fold cross-validation that assess performance 
by resampling the training set have been developed to overcome 
the constraints of limited data [25, 26]. Thus, we also compared 
cross-validation and IV, as well as different approaches to par-
titioning samples to create training and validation sets. In addi-
tion, we assessed whether the sleep debt status of an individual 
can be assessed without any prior knowledge about the individ-
ual (between subject assessments) or whether prior knowledge 
(within subject assessment) is required.
Methods
Source of data and definitions of various indices of 
sleep debt status
Data were collected in a previously described study that 
received a favorable opinion from the University of Surrey’s 
Ethics committee in accordance with the guidelines laid down 
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in the Declaration of Helsinki. All participants provided written 
informed consent [18]. The chronic sleep debt status of 36 (18 
males; mean ± SD of age = 27.6 ± 4.0 years) healthy participants 
without sleep disorders and having an average actigraphically 
assessed habitual time in bed (TIB) of 8  hr and 18  min, was 
manipulated by enforcing 1 week of insufficient sleep (6 hr TIB, 
mean ± SEM of polysomnography [PSG] assessed total sleep 
time [TST] of 5.75 ± 0.06 hr) and sufficient sleep (10 hr TIB, mean 
± SEM of PSG assessed TST of 8.56 ± 0.06 hr) under carefully 
controlled clinical research center conditions in a balanced 
crossover design (see Figure 1 and [2]). In these same partici-
pants, acute sleep debt status was manipulated by enforcing a 
39–41 hr period of wakefulness (total sleep deprivation), under 
constant routine conditions, immediately following the week 
of sufficient and insufficient “sleep history” condition. In the 
constant routine condition, participants were in a semi-recum-
bent position under constant dim light. Their caloric needs 
were met by hourly “nutritional beverages.” Three-hourly 
(nonfasting) whole-blood RNA samples, labeled samples #1 
to #10, were collected through an indwelling cannula in the 
participant’s forearm (without heparin) during each of these 
total sleep deprivation periods from each participant. The first 
sample (#1) was taken at approximately 15:00–16:00 hr, that is, 
7–8 hr after scheduled wake time, and sample #10 at approxi-
mately 18:00–19:00 hr, that is, 34–35 hr after scheduled wake 
time. These data represent an extension of the data previously 
analyzed [18].
Based on this data set, we explored the feasibility of bio-
marker development for the variables:
1. Time awake, the number of hours awake, given a blood sam-
ple taken at any time of day.
2. Wakefulness of more than 24 hr, given a blood sample taken 
at any time of day.
3. Acute sleep loss (skipped a night of sleep), given a blood 
sample taken in the afternoon.
4. Chronic sleep insufficiency, given a blood sample taken in 
the afternoon.
5. Sleep increase/decrease, given two blood samples of an indi-
vidual taken on different occasions.
Ideally a biomarker should be able to identify the status of an 
individual by assessing the value of the biomarker without any 
information about the value of the biomarker in that individ-
ual in another state, that is, the value of the biomarker can be 
compared with the population distribution to assess status. In 
cases in which the subject-specific (“trait” like) variation in the 
value of the biomarker is large compared with the “state” like 
variation, status can only be assessed by assessing changes in 
the biomarker within an individual. For example, the notion 
that slow-wave sleep is a biomarker of sleep homeostasis is 
largely based on within-subject changes and the between-sub-
ject variation, which is large, is ignored. Likewise, the human 
transcriptome is highly individual [27] and this poses a chal-
lenge for the development of biomarkers that can predict the 
sleep debt status of individuals by a between-subject compari-
son. A  between-subject approach is nevertheless preferable. 
We have therefore compared biomarkers which can be used 
for a between-subject comparison (based on single, indepen-
dently collected transcriptome samples; predictor algorithms 
are blind to the subject from whom a sample is taken) and bio-
markers which can be used for a within-subject assessment of 
sleep debt status, or more precisely, assessment of a change in 
sleep debt status.
Creation of training and validation data sets
Following quality control assessments (i.e. sufficient quality and 
quantity of RNA), at least one whole-blood transcriptome sam-
ple was obtained for 36 participants, with a total of 496 tran-
scriptome samples across the study (254 following 1 week of 
sufficient sleep, 242 following 1 week of insufficient sleep). All 
Figure 1. Protocol. In a crossover design participants entered a constant routine following either 1 week of sufficient (mean ± SEM of PSG assessed TST of 8.56 ± 0.06 hr) 
sleep or 1 week of insufficient (mean ± SEM of PSG assessed TST of 5.75 ± 0.06 hr) sleep. During the constant routine of 39–41 hr of wakefulness blood samples were 
collected 3 hourly for transcriptome samples (samples labeled #1 to #10) and hourly for melatonin assessments. At the end of each constant routine participants were 
given a 12 hr recovery period. Melatonin curves (gray area) represent the average melatonin curve (across all participants) during the constant routine for sufficient 
and insufficient sleep, respectively.
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raw data are accessible from the Gene Expression Omnibus [28] 
(Accession numbers: GSE39445 and GSE82114).
Two different approaches were taken to create pairs of 
training and validation sets from the 496 samples (Figure  2); 
(1) “unique participants and unique samples” (UPUS), where 
all samples collected from a single participant were included 
in either the training or validation set, and the training and 
validation sets each comprise a unique set of participants; (2) 
“overlapping participants and unique samples” (OPUS), where 
all samples collected from a participant during one sleep his-
tory condition (sufficient or insufficient sleep) were included 
in the training set, and all samples collected during the 
alternate sleep history condition were included in the valida-
tion set. In this split, all participants are present in both the 
training and validation sets, and it is only the samples that 
are unique between sets (with sleep history conditions bal-
anced within each set). Partitioning the entire data set by these 
two approaches was conducted randomly while ensuring that 
relevant participant characteristics such as gender were bal-
anced across the training and validation sets. The structure 
of the training and validation sets remained the same across 
all analyses except for the sleep variable “sleep increase/
decrease,” where an additional factor “clinic visit” was required 
to be balanced. Where analyses rely on a subset of samples 
Figure 2. Overview of our approach to identifying panels of biomarkers and assessing their performance.
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the nonrelevant samples were discarded from the training and 
validation sets. The processed data sets are available at http://
sleep-sysbio.fhms.surrey.ac.uk/SleepDebt.
Data processing
The log2 mRNA abundance values within each sample were 75th 
percentile normalized. Noncontrol technically replicated probes 
(mRNA abundance features), along with their correspond-
ing Agilent feature flags (Agilent Feature Extraction Software 
[v10.7], Reference Guide, publication number G4460-90036) were 
averaged. Following standard operating procedures, features 
(probes) flagged as poor quality based on AgilentQC metrics of 
reproducibility statistics, minimum detection level estimates, 
and feature flags (Agilent Feature Extraction Software [v10.7], 
Reference Guide, publication number G4460-90036) in more than 
10% of the samples within the training set were removed. Thus, 
each training-validation data set pair were distinct in the num-
ber of samples, participants, and probes that they contain. For 
within-subject assessments, each sample within a data set was 
transformed to reflect the change in mRNA abundance between 
the reference and test sample (e.g. sample #2 − sample #1 [base-
line]). This procedure removes the trait-like (i.e. participant spe-
cific) characteristics of the blood transcriptome and thereby may 
facilitate the changes in the transcriptome associated with the 
sleep intervention.
Feature selection
As each processed transcriptome sample comprises ~20 k mRNA 
abundance features (probes), with one or more features target-
ing transcripts of a single gene, we applied different approaches 
to select features. Approaches involved the use of a priori knowl-
edge (i.e. using prefiltered features) and the use of penalized 
(regularized) linear regression techniques with and without pre-
filtered features.
Regularization is a method by which the complexity of a 
model can be controlled through the use of penalties. Penalties 
referred to as L1 norm and L2 norm are used to control the least 
absolute error and/or least squares error between the predicted 
and observed target value, respectively. High L1 norm penalties, 
such as applied in LASSO regression [22], produce sparse, low 
complexity models. A reduced subset of all features is selected 
to predict the desired outcome, where the selection of a “rep-
resentative” feature(s) from a set of highly correlated features 
is arbitrary. Conversely, L2 norm penalties, such as applied in 
ridge regression [29], produce more complex models compris-
ing all features (no selection) with small distributed weights. 
Alternative, “hybrid” methods, such as elastic net regression 
[23], combine the L1 and L2 penalties to generate sparse models 
(as per LASSO) whilst allowing for all correlated features, such 
as those targeting transcripts encoding proteins involved in the 
same pathway/biological process, to appear in the model (as per 
ridge) [23]. For studies aiming to identify putative blood based 
biomarkers, and not just develop a prediction/classification 
model, elastic net has shown great promise [30].
Feature selection using a priori knowledge
It may be argued that a biomarker for acute total sleep loss 
should neither be influenced by the circadian phase at which a 
sample is taken, nor the prior sleep history. Thus, in our prefil-
tering approach features were selected a priori based on their 
own independent mRNA abundance profiles across time, from 
our within-subject analyses of a subset of the current data 
reported in Möller-Levet et al. [18]. Features selected a priori 
for models associated with hours awake, herein referred to 
as the “hours awake” a priori selected set of features, met the 
criteria that: (1) their mRNA abundance profiles displayed a 
significant positive/negative trend across time following both 
sufficient and insufficient sleep, (2) their profiles did not dis-
play a significant circadian modulation during the time awake 
period, and (3) their profiles were not significantly different 
between sleep history conditions. Features selected a priori 
for models associated with predicting the sufficiency of sleep 
(e.g. sleep history of 10 hr TIB vs. 6 hr TIB), herein referred to 
as the “sleep sufficiency” a priori selected set of features, met 
the criteria that: (1) their mRNA abundance profiles displayed 
significant differences between sleep history conditions, (2) 
their profiles did not display a significant circadian modula-
tion during the time awake period, and (3) their profiles did 
not display a significant positive or negative trend across 
time, that is, were not affected by acute sleep loss. Prediction/
classification models generated from features selected by a 
priori knowledge were developed using ridge regression. Due 
to the independent data processing applied not all of the a 
priori selected features may appear within a given training 
set. Table  1 details the number of a priori selected features 
available for training.
Feature selection using elastic net regression
Elastic net regression was used to concurrently select features 
and produce a linear regression model for predicting/classi-
fying a given sleep debt variable using: (1) all features (no a 
priori knowledge), or (2) an a priori selected set of features, 
as input.
There are two tuning hyper-parameters that influence 
feature selection and model construction in penalized regres-
sion approaches such as elastic net regression: alpha, which 
controls the balancing of L1 norm and L2 norm penalties, 
and lambda, which controls the level of the penalty(s) given 
alpha. Here, alpha was set to 0.5 for elastic net regression and 
0 for ridge regression. To determine the value of lambda, we 
performed a 10-fold cross-validation search for the lambda 
value that gives the minimum mean cross-validated error 
when applied to the given training set. Folds of the training 
set were assigned randomly, albeit with respect to the bal-
ance of classes within the training set, and thus repeated 
500 times. The mean value of the selected lambda across 
the 500 searches was subsequently defined as the “optimal” 
lambda value for creating the final prediction/classification 
model based on all samples within the training set. Features 
with nonzero coefficients within the final model were 
defined as biomarkers relevant for predicting/classifying the 
target value.
The performance of the final model (panel of biomarkers) 
was assessed using (1) leave-one-subject-out cross-validation 
(LOSO-CV) of the training set (a different strategy to the cross-
validation approach applied when selecting lambda), and (2) 
IV using the corresponding independent validation test set. 
Comparing LOSO-CV and IV performance we were able to iden-
tify any “overfitting” of the model to the training set, a common 
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problem when using small data sets [26]. All models were devel-
oped and tested using the glmnet package (version 2.0–13) [31] 
in R (version 3.3.3) [32].
Measuring model performance
Prediction models used to predict a quantitative target value yˆ  
(e.g. number of hours awake) were linear regression models of 
the form:
yˆ x xn n= β β β0 1 1+ + …
where x are all features provided as input, β the coefficients 
assigned to each feature by the penalized regression approach, 
and the intercept β0. All input features appear in the model. 
Features not selected by penalized regression were assigned a 
coefficient of 0. Performance of such models was assessed by R2, 
a measure of the fit between the predicted yˆi  and observed yi 
target value for each of the transcriptome samples comprising x 
features within the test set:
R
y y
y y
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i i
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Classification (logistic regression) models used to classify a sam-
ple/individual into one of two classes were of the form:
yˆ
n n
n n
x
x
=
+
+ …
+ …
e
e
x
x
β β β
β β β
0 1 1
0 1 11
where x are all features provided as input, β the coefficients 
assigned to each feature by penalized regression, and the inter-
cept β0.  All features appear in the model, with only selected 
features having a nonzero coefficient. Here, yˆ  represents the 
probability that a participant with a given mRNA abundance 
value for features x belongs to a given class. The use of the term 
eβ β β0 1 1+ x xn n...  in both the numerator and denominator ensures that 
output value yˆ will fall between 0 and 1.  As samples belong-
ing to each class were balanced as much as possible within the 
training and validation sets, the prior probabilities for each class 
were 0.5. Thus, the decision boundary of 0.5 was used to assign 
a transcriptome sample to a particular class.
For classification the target class  variable (e.g. “chronic 
sleep insufficiency,” or “acute sleep loss”) was considered to 
be the “positive” class, and the alternate class (e.g. “no chronic 
sleep insufficiency” or “no acute sleep loss”) was considered to 
be the “negative” class. Subsequently, we were able to deter-
mine the number of true positives (TP), true negatives (TN), 
false positives (FP), and false negatives (FN). The performance 
of a classification model was assessed by overall accuracy 
[TP + TN/(TP + TN + FP + FN)], sensitivity [TP/(TP + FN)], speci-
ficity [TN/(TN + FP)], and Matthew’s correlation coefficient 
[MCC: TP.TN-FP.FN (TP+FP)(TP+FN)(TN+FP)(TN+FN)/ ], a con-
sistent measure of model accuracy invariant to the balancing 
of samples [33].
Figures for visualization of model performance, and features’ 
mRNA abundance profiles were created in R (version 3.3.3) [32] 
using packages: heatmap3 (version 1.1.1) [34], gplots (version 
3.0.1) [35], and Hmisc (version 4.1-1) [36].
Calculating effect size
Cohen’s d effect size, the difference in the mean predicted value 
M between two groups in pooled (across the two groups) SD (s) 
units, was calculated by:
d =
M M
s
1 2−
pooled
Groupings were based on the observed value for the variable 
“time awake, between-subject.”
Functional analysis and interpretation of panels of 
biomarkers
Each panel of biomarkers was transformed to a list of unique 
gene symbols (indicated in Table 1). Statistical functional enrich-
ment analysis was performed on each gene list using the online 
tool Metascape [37] at www.metascape.org (based on annotation 
update on January 1, 2018) with default settings and the human 
protein-encoding genome as the background. Information on 
gene function/interactions was sourced from the GeneCards data-
base [38] at www.genecards.org (v4.7.2) and UniProt [39] at www.
uniprot.org (release 2018_03). The full list of gene ontology (GO) 
annotations for all gene symbols was downloaded from UniProt 
[39] at www.uniprot.org (release 2018_03). This annotation was 
used to identify the “top 10” enriched GO terms for each panel 
of biomarkers, where enrichment is based on the proportion of 
genes in the list associated with a GO term (no statistical test 
applied). Known and inferred functional interactions between 
genes were extracted from the STRING database [40] at string-db.
org (v10.5) using default settings. Briefly, confidence in the associ-
ation (functional interaction) of a pair of genes was calculated by 
combining several sources of evidence, including experimentally 
observed interactions in human and/or other species, inference 
based on text-mining and conservation across multiple species. 
A pair of genes having a combined confidence score of at least 0.4, 
which excludes low quality confidence scores, were considered 
to be associated and thus appear connected by an edge in the 
resultant functional interaction network. Redrawing of STRING 
inferred networks and network analysis (degrees for each node in 
the network) was conducted using Cytoscape (version 3.2.1 [41]). 
All connected nodes were included.
Results
Biomarker performance
Table 1 lists the number of features and unique genes, and the corre-
sponding LOSO-CV and IV performance for all panels of biomarkers 
identified and validated using the UPUS data sets. Supplementary 
Table S1 provides the same information for panels of biomarkers 
identified and validated using OPUS data. Performance plots not 
shown and discussed herein (e.g. performance of all a priori knowl-
edge informed panels of biomarkers, and panels identified using 
OPUS data) are provided in Supplementary File S1.
Biomarker panels for acute sleep loss
Predicting “time awake”; between-subject assessment. We 
first investigated whether it is possible to predict the time an 
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individual has been awake from one blood transcriptome sam-
ple. Every sample was assigned a time awake value ranging 
from 7 to 35 hr (Figure 1). Training and corresponding validation 
sets included all samples and were submitted to the workflow 
(Figure  2) to identify and validate biomarker panels for “time 
awake” using different approaches.
The panels of biomarkers identified as having the best per-
formance, highest R2 value, were obtained when using “all fea-
tures” and elastic net (UPUS R2 = 0.29, OPUS R2 = 0.39). These panels 
comprised 59 (UPUS) and 211 (OPUS) features. The LOSO-CV and 
IV performance of panels identified and validated from the train-
ing and validation sets were similar, although IV performance 
was somewhat lower than LOSO-CV (Table  1, Supplementary 
Table S1). Panels identified and validated using OPUS data yielded 
higher performance (R2 range between 0.23 and 0.31 for UPUS, 
0.28 and 0.45 for OPUS). However, the R2 values obtained from all 
searches is considered poor, with less than 50% of the observed 
variance in the values of “time awake” explained (Figure 3a).
Predicting “time awake”; within-subject assessment. Our pre-
vious analyses of a subset of the current data identified 22,401 
features for which there is a significant effect of time on mRNA 
abundance within a participant [18]. Our above approach to pre-
dicting “time awake” does not consider the individual. Here, we 
further processed all mRNA abundance values to reflect change 
from the participant’s baseline (sample #1). Each baseline-cor-
rected transcriptome sample was assigned the same time awake 
value as the nonbaseline corrected sample and used to identify 
biomarkers for “time awake” within an individual. Baseline cor-
rection (within participant comparison) did not improve pre-
diction performance and all R2 values were weak (R2 range of 
0.15–0.44 across approaches) and similar to that observed when 
predicting “time awake” without considering the individual 
(Figure 3). The “all features” elastic net approach again identified 
panels with the highest performance. However, the panels from 
the two-sample approach were of different size to those identi-
fied by the one-sample approach (74 UPUS, 184 OPUS).
Table 1. Size and performance of biomarker panels for the prediction/classification of different sleep debt variables
Biomarkers for
Number of samples 
within the training 
and independent 
validation sets
Number of features (unique  
genes) in the final model LOSO-CV performance IV performance
a priori 
knowledge 
and ridge
a priori 
knowledge  
and elastic net
All features  
and elastic net
a priori 
knowledge  
and ridge
a priori 
knowledge  
and elastic net
All features  
and elastic net
a priori 
knowledge  
and ridge
a priori 
knowledge  
and elastic net
All features 
and elastic 
net
A
cu
te
 s
le
ep
 lo
ss
 v
ar
ia
bl
es
Prediction of “time awake, 
between-subject”; samples 
#1 to #10
 Training = 239 
Validation = 233
26 (26) 17 (17) 59 (58) R2 = 0.31 R2 = 0.30 R2 = 0.35 R2 = 0.23 R2 = 0.22 R2 = 0.29
Prediction of “time awake, 
within-subject”; sample #2 
- sample #1, #3 - #1, #4 - #1, 
#5 - #1, #6 - #1, #7 - #1, #8 - #1, 
#9 - #1, #10 - #1
 Training = 185 
Validation = 189
26 (26) 9 (9) 74 (73) R2 = 0.23 R2 = 0.25 R2 = 0.44 R2 = 0.22 R2 = 0.24 R2 = 0.30
Classification of “wakefulness 
of more than 24 hr, between-
subject”; all samples, based 
on the predicted “time awake” 
value
 Training = 239 
Validation = 233
26 (26) 17 (17) 59 (58) ACC = 75% 
Sn = 61% 
Sp = 84% 
MCC = 0.47
ACC = 74% 
Sn = 61% 
Sp = 84% 
MCC = 0.46
ACC = 79% 
Sn = 66% 
Sp = 89% 
MCC = 0.57
ACC = 74% 
Sn = 50% 
Sp = 91% 
MCC = 0.46
ACC = 73% 
Sn = 49% 
Sp = 88% 
MCC = 0.42
ACC = 80% 
Sn = 70% 
Sp = 87% 
MCC = 0.59
Classification of “acute sleep 
loss, between-subject”; sam-
ples #1 vs. sample #9
 Training = 50 
Validation = 49
26 (26) 20 (20) 68 (68) ACC = 76% 
Sn = 71% 
Sp = 79% 
MCC = 0.51
ACC = 72% 
Sn = 76% 
Sp = 69% 
MCC = 0.45
ACC = 76% 
Sn = 76% 
Sp = 76% 
MCC = 0.52
ACC = 76% 
Sn = 52% 
Sp = 93% 
MCC = 0.51
ACC = 76% 
Sn = 57% 
Sp = 89% 
MCC = 0.5
ACC = 92% 
Sn = 90% 
Sp = 93% 
MCC = 0.83
Classification of “acute sleep 
loss, within- 
subject”; difference between 
sample #2 and #1 vs. difference 
between sample #10 and #1
 Training = 41 
Validation = 43
26 (26) 12 (12) 32 (31) ACC = 88% 
Sn = 87% 
Sp = 89% 
MCC = 75%
ACC = 93% 
Sn = 87% 
Sp = 100% 
MCC = 0.86
ACC = 90% 
Sn = 83% 
Sp = 100% 
MCC = 0.82
ACC = 77% 
Sn = 72% 
Sp = 83% 
MCC = 0.55
ACC = 74% 
Sn = 68% 
Sp = 83% 
MCC = 0.51
ACC = 74% 
Sn = 72% 
Sp = 78% 
MCC = 0.49
C
h
ro
n
ic
 s
le
ep
 lo
ss
 v
ar
ia
bl
es
Classification of “chronic sleep 
insufficiency”; samples #1 or #2 
for insufficient sleep vs. sam-
ples #1 or #2 for sufficient sleep
 Training = 30 
Validation = 30
407 (407) 14 (14) 9(9) ACC = 60% 
Sn = 67% 
Sp = 53% 
MCC = 0.2
ACC = 53% 
Sn = 53% 
Sp = 53% 
MCC = 0.07
ACC = 53% 
Sn = 60% 
Sp = 47% 
MCC = 0.07
ACC = 57% 
Sn = 62% 
Sp = 53% 
MCC = 0.14
ACC = 47% 
Sn = 54% 
Sp = 41% 
MCC = -0.05
ACC = 50% 
Sn = 77% 
Sp = 29% 
MCC = 0.07
Classification of “chronic sleep 
insufficiency”; samples #9 or 
#10 for insufficient sleep vs. 
samples #9 or #10 for suffi-
cient sleep
 Training = 34 
Validation = 30
420 (420) 7 (7) 21 (21) ACC = 59% 
Sn = 65% 
Sp = 53% 
MCC = 0.18
ACC = 59% 
Sn = 71% 
Sp = 47% 
MCC = 0.18
ACC = 47% 
Sn = 47% 
Sp = 47% 
MCC = -0.06
ACC = 53% 
Sn = 38% 
Sp = 71% 
MCC = 0.09
ACC = 57% 
Sn = 50% 
Sp = 64% 
MCC = 0.14
ACC = 47% 
Sn = 44% 
Sp = 50% 
MCC = -0.06
Classification of “sleep 
decrease/increase”;  
difference in sample #2 or sam-
ple #3 from visit 1 and sample 
#2 or sample #3 from visit 2
 Training = 10 
Validation = 9
413 (413) 13 (13) 36 (34) ACC = 70% 
Sn = 80% 
Sp = 60% 
MCC = 0.41
ACC = 50% 
Sn = 60% 
Sp = 40% 
MCC = 0
ACC = 50% 
Sn = 60% 
Sp = 40% 
MCC = 0
ACC = 89% 
Sn = 100% 
Sp = 80% 
MCC = 0.8
ACC = 78% 
Sn = 100% 
Sp = 60% 
MCC = 0.63
ACC = 78% 
Sn = 100% 
Sp = 60% 
MCC = 0.63
Classification of “sleep 
decrease/increase”; difference 
in sample #9 or sample #10 
from visit 1 and sample #9 or 
sample #10 from visit 2
 Training = 14 
Validation = 15
413 (413) 18 (18) 62 (62) ACC = 64% 
Sn = 57% 
Sp = 71% 
MCC = 0.29
ACC = 71 % 
Sn = 71% 
Sp = 71% 
MCC = 0.43
ACC = 71% 
Sn = 71% 
Sp = 71% 
MCC = 0.43
ACC = 67% 
Sn = 100% 
Sp = 44% 
MCC = 0.49
ACC = 53%  
Sn =83 % 
Sp = 33% 
MCC = 0.18
ACC = 40% 
Sn = 83% 
Sp = 11% 
MCC = -0.08
Data shown for models based on “UPUS” training and validation sets only.
ACC = classification accuracy, Sn = sensitivity, Sp = specificity, MCC = Matthew’s correlation coefficient.
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Classifying wakefulness of more than 24 hr; between-subject 
assessment. A second question is whether we can reliably pre-
dict whether an individual has been awake for more than 24 hr 
or not. While the R2 values between predicted and observed 
“time awake” values were poor, the panels clearly predict a trend 
in time awake. The average predicted value for a given observed 
value of “time awake” was typically higher than the average pre-
dicted value for the preceding values of “time awake” (Figure 3). 
Indeed, the effect sizes between the predicted values for each 
observed “time awake, between-subject” value pair were greater 
than 0.2 SDs (effect size d > 0.2; Figure 4a). Large (d > 0.8) effect 
sizes were observed when comparing the mean predicted “time 
awake, between-subject” values for sampling points #1 to #6 
(awake less than 24 hr) with that of samples #7 to #10 (awake 
more than 24 hr). This breaking point in effect size suggested 
that the predicted “time awake” values may be used to clas-
sify a sample. Thus, for every observed “time awake, between-
subject” value, we assessed the percentage of predicted values 
having a value greater than 24 hr. As expected, the distributions 
of these percentage values were distinct for observed “time 
awake, between-subject” values of <24 hr and >24 hr (Figure 4b). 
Subsequently, for a given panel of biomarkers, we used a sam-
ple’s predicted “time awake, between-subject” value to assign it 
to one of two classes; “awake < 24 hr” or “awake > 24 hr,” with 
“awake > 24 hr” considered to be the “positive” class.
The “all features” and elastic net approach was again found 
to produce the greatest performance with an overall classifica-
tion accuracy of 79% (OPUS) to 80% (UPUS) (Table 1, Figure 4c). All 
panels of biomarkers were more specific (specificity: 84%–91%) 
in their classification than sensitive (sensitivity: 49%–70%).
Classifying “acute sleep loss” without confounding by circadian 
phase; between-subject assessment. In all analyses presented 
thus far, circadian phase and time awake changed simultan-
eously. We next addressed whether it is possible to determine 
if a sample taken at a particular circadian phase comes from 
an individual who has been awake during the preceding 24 hr 
(i.e. skipped one night of sleep). Indexing samples by clock time, 
each sample was assigned to either class of “acute sleep loss” or 
“no acute sleep loss” by the presence/absence of sleep within the 
same 24 hr clock period. Samples #1 and #9 from both sleep his-
tory conditions were retained because both samples were col-
lected at the same time of day without the confounding effect 
of circadian phase and represent negative and positive cases of 
“acute sleep loss,” respectively.
The IV classification performance of the identified panels of 
biomarkers ranged from 75% to 92% (Table 1, Supplementary File 
S1, Figure 5a). The LOSO-CV performance was similar. The com-
bination of “all features” and elastic net applied to UPUS data 
produced a panel with the highest classification performance 
(92% accuracy, MCC = 0.83), due to greater levels of sensitivity 
(sensitivity  =  90% compared with <60% in other UPUS based 
searches). The performance of the predictors for acute sleep loss 
appeared similar for the two sleep history conditions (Figure 5a, 
left panel). For the between participant approaches, panels 
based on UPUS data tended to be more specific than sensitive, 
while OPUS-based panels were more sensitive than specific. The 
number of features identified was not markedly different (68 
UPUS, 48 OPUS). Figure 5b demonstrates the robustness of the 
best performing panel. Within the training set, there is a clear 
distinction in mRNA abundance levels of all features between 
samples (participants) of each class. In the corresponding valid-
ation set the difference is not so distinct. Some individual fea-
tures fail to produce the expected signal in the validation set. 
However, when the entire panel is considered the separation 
between samples is clear and a performance of 92% accuracy 
Figure 3. Prediction performance for “time awake” between- and within-subject. Prediction of “time awake” from one (between-subject) or two (within-subject) tran-
scriptome samples. Blue: samples taken following 1 week of sufficient sleep; gold: samples taken following 1 wk of insufficient sleep. Dashed line indicates the line of 
unity. Red line indicates a linear regression of the relationship of predicted and observed. Data shown is based on the final “all features” elastic net model trained on 
all samples within the “UPUS” training set and applied to all samples within the corresponding independent validation set.
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is achieved (Figure 5a). Example mRNA abundance profiles for 
the biomarker A_23_P205273 (probe targeting a transcript of the 
gene PP1R13B) for “acute sleep loss, between-subject” are shown 
in Supplementary File S2.
Classifying “acute sleep loss” without confounding by circadian 
phase; within-subject assessment. To remove the potential con-
found of circadian phase and possibly improve the classification 
performance of “acute sleep loss,” we performed a within par-
ticipant analysis comparing sample #2 (no acute sleep loss) with 
the 24 hr separated sample #10 (acute sleep loss) after having 
subtracted sample #1 from both (i.e., correcting for the baseline 
condition within each participant).
Baseline correction for the variable “acute sleep loss” did 
not improve upon the performance achieved when using a 
single, nonbaseline-corrected transcriptome sample (Figure 5). 
However, in contrast to the between participant approach, when 
baseline correction was applied the a priori selected features 
were able to classify samples with similar, or greater accuracy 
than those selected from “all features.” This is expected as the 
a priori features were selected using within individual analyses.
Biomarker panels for chronic sleep loss
Classifying “chronic sleep insufficiency”; between-subject 
assessment. For “chronic sleep insufficiency,” we assessed 
whether it is possible to determine if a sample taken in the 
afternoon comes from an individual who has had less than 
6 hr of sleep over an extended period (1 week). All samples 
were labeled by the sleep history condition in which they 
were collected. Training and validation sets comprised sam-
ple #1 from each sleep history condition. Where sample 
#1 was not available for a participant sample #2 was used 
instead.
In contrast to “time awake” and “acute sleep loss,” the bet-
ter performing panels of biomarkers for “chronic sleep insuffi-
ciency” were derived from the “sleep sufficiency” a priori selected 
feature list. However, the highest IV classification accuracy 
achieved was only 57% (Figure 6a). The structure of the training 
and validation sets had an impact on performance. For OPUS 
data, the IV classification performance was worse than random 
classification (expected accuracy of 50%). This complete mis-
classification of samples was due to the effect of the individ-
ual within the design of the OPUS training and validation sets. 
The validation samples from a participant providing “sufficient 
sleep” samples to the OPUS training set were classified as “suffi-
cient sleep” in the IV. Similarly, with “insufficient sleep” samples. 
Hence, the negative MCC values (range = −0.45 to −0.17). We can 
only assume this is because elastic net has identified a related, 
but currently unknown, variable that can stratify participants. 
For this reason, we see a larger impact on IV performance in the 
“all features” list, which is reduced when the effect of the indi-
vidual is removed in LOSO-CV. The number of features selected 
was similar (9 UPUS, 11 OPUS).
The effects of insufficient sleep on many physiological and 
behavioral variables are exacerbated by acute sleep deprivation 
[18]. Therefore, a pertinent question to ask is whether sample 
#9 (or #10), collected at the same time of day as #1 (or #2), but 
following a period of total sleep deprivation, emphasizes the 
changes in the blood transcriptome in response to 1 week of 
chronic sleep insufficiency and improves classification accuracy. 
Hence, we repeated the above described analysis with sample 
#9 (or #10). The panels identified did not improve performance 
(highest classification accuracy of 57%), even with a greater 
number of biomarkers within the panel (21 UPUS, 36 OPUS).
Classifying “sleep increase/decrease”; within-subject assess-
ment of sufficient versus insufficient sleep. Clinics/researchers 
monitoring changes in sleep behavior over time may benefit 
from having a panel of biomarkers able to identify changes in 
sleep duration (i.e. an increase or decrease) within an individ-
ual. Thus, we investigated whether it is possible to identify indi-
viduals who have gained or lost sleep. Within the constraints 
Figure 4. Predicted “time awake” value for classifying “wakefulness of >24 hr.” (a) Difference between the mean predicted value of “time awake” for samples collected 
at x hours awake and samples collected at y hours awake. Difference expressed as Cohen’s d effect size. Data based on predictions made for samples within the “UPUS” 
training data set when using the “all features” elastic net model for “time awake” trained on all samples within the “UPUS” training data set. No baseline correction 
applied. (b) Percentage of samples predicted to have a “time awake” value of greater than 24 hr for all observed values of “time awake.” Data based on predictions made 
for samples within the “UPUS” validation data set when using the “all features” elastic net model for “time awake” trained on all samples within the “UPUS” training 
data set. (c) Classification performance when classifying a sample within the “UPUS” validation set to one of two classes, “awake > 24 hr,” “awake < 24 hr” using the 
predicted “time awake” value of a sample using the “all features” elastic net model for “time awake” trained on all samples within the “UPUS” training data set. Black 
horizontal line represents the decision boundary at 24 hr. ACC = accuracy, SS= samples from sufficient sleep condition, IS = samples from insufficient sleep condition.
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of our protocol this translates to distinguishing the participants 
subjected to 1 week of insufficient sleep followed by 1 week of 
sufficient sleep, from the participants subjected to 1 week of suf-
ficient sleep followed by 1 week of insufficient sleep. We used 
only the UPUS training and validation sets comprising the dif-
ference in mRNA abundance between a sample of the first “visit” 
and its corresponding sample from the second “visit” within a 
participant. We searched for biomarker panels for each of the 
10 differential sampling points. Where a given sampling was 
unavailable for a participant the sample from the subsequent 
sampling point was used, for example, if sample #1 was not 
available we took sample #2 (for sample #10, sample #9 was used 
if #10 was not available).
Comparing across sampling points, the highest classification 
accuracy was provided by sample #2 (or #3), equivalent to sam-
pling between 11:00 and 14:00 hr (Figure 6, Supplementary File 
S1). Table 1 summarizes results for sample #2 and, as a contrast, 
sample #9 (or #10). Relatively few features were selected by elastic 
Figure 5. Classification performance for “acute sleep loss” between- and within-subject. (a) Classification of a sample to two classes: “acute sleep loss” and “no acute 
sleep loss.” “Between-subject” refers to the classification of “acute sleep loss” from a single transcriptome sample, collected at 7–8 hr or 31–32 hr of time awake. 
“Within-subject” refers to the classification of “acute sleep loss” from a baseline-corrected transcriptome sample collected at 10–11 hr or 34–35 hr of time awake. Black 
horizontal line represents the decision boundary for classifying a sample at a probability of 0.5. Blue: samples taken following 1 wk of sufficient sleep; gold: samples 
taken following 1 week of insufficient sleep, gray: all samples. Data shown based on the final “all features” elastic net model trained on all samples within the “UPUS” 
training set and applied to all samples within the corresponding independent validation set. ACC = accuracy. (b) Distribution of mRNA abundance values for features 
selected as classifiers of the sleep debt variable “acute sleep loss” when applying elastic net to “all features” within the “UPUS” training set (without baseline correction). 
mRNA abundance data is shown for all samples within the “UPUS” training and validation sets with no baseline correction.
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net from “all features” (36 from #2 [or #3], 62 from #9 or [#10]). 
Panels based on the “sleep sufficiency” a priori features gave 
the greatest IV classification accuracy (89% and 67% accuracy, 
0.8 and 0.49 MCC for samples #1 and #9, respectively). However, 
the better performance does not appear to be directly related to 
the increased number of features in the panel (Supplementary 
Figure S1). The striking difference between LOSO-CV and IV clas-
sification performance (ca. 20% difference in accuracy) we expect 
to be an effect of the reduced number (10 samples in the train-
ing set) and variance between samples. Indeed, the high clas-
sification performance is not realized as a prominent distinction 
between classes’ mRNA abundance profiles within the validation 
set (Supplementary Figure  S2). An example of a biomarker for 
“sleep increase/decrease” is shown in Supplementary File S2.
Functional annotation of mRNA biomarker panels
We next investigated the process associated with the vari-
ous panels predicting sleep debt status. All panels of mRNA 
biomarkers and their associated genes are provided in data 
set S1. A comparison of the genes associated with each panel 
is provided in data set S2. Here, we focus on the functional 
interpretation and overlap of panels identified by (1) a priori 
knowledge, and (2) selected by applying elastic net to UPUS 
training sets.
Biomarker panels for acute sleep loss
a priori knowledge informed panels for acute sleep loss. Genes 
with known function associated with the 26  “hours awake” a 
priori selected features are involved in lipid metabolism (ABCA1, 
PTPLB [HACD2]), ubiquitination (HECTD3, UBE2V1), centro-
some function and the regulation of mitosis/meiosis (C6orf204 
[CEP85L], C1orf96 [CCSAP], NEK1, NCAPD2), actin binding (TPM4), 
ATPase binding (TOR1AIP2), insulin signaling (STXBP4), and regu-
lation of cardiomyogenic differentiation [42] and cell prolifer-
ation via MAPK, PI3K/AKT, and JAK/STAT signaling (PARM1) [43]. 
Many features were associated with the regulation of transcrip-
tion/translation; three DNA binding histone proteins (HIST1H3J, 
HIST1H4J, HIST1H4K), a subunit of the mediator complex that 
activates RNA polymerase II (MED9), a phosphoinositide 3-kin-
ase (PI3K) regulatory subunit that regulates mTOR-mediated 
gene expression and is involved in glucose uptake and insulin 
Figure 6. Classification performance for “chronic sleep insufficiency” between- and within-subject. “Between-subject” refers to the classification of a single transcrip-
tome sample to two classes: following sufficient sleep (SS) or following insufficient sleep (IS). Data shown based on the final “all features” elastic net model trained on all 
samples #1 (or #2) within the “UPUS” training set and applied to all samples #1 (or #2) within the corresponding independent validation set. “Within-subject” refers to the 
classification of a differential transcriptome sample to two classes: sleep decrease or sleep increase. Data shown based on the final “all features” elastic net model trained 
on all “visit 1”–“visit 2” samples, using samples #2 (or #3), within the “UPUS” training set and applied to all “visit 1”–“visit 2” samples, using samples #2 (or #3) within 
the corresponding independent validation set. Black horizontal line represents the decision boundary for classifying a sample at a probability of 0.5. ACC = accuracy.
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signaling (PIK3R3), a coiled-coil domain protein that inhibits 
β-catenin and negatively regulates WNT-driven gene expres-
sion (CCDC88C), and an RNA methyltransferase that regulates 
ribosomal biogenesis (FTSJ3). The “hours awake” set of features 
was used as input to four elastic net searches (“time awake” and 
“acute sleep loss” using within- and between-subject assess-
ments). Ten of the 26 features were selected in three of the four 
searches, including PARM1, FTSJ3, PIK3R3, PARM1, HIST1H4K, 
C1orf96 (CCSAP), and TOR1AIP2, with PARM1 and FTSJ3 present 
in all four panels.
Panels for acute sleep loss selected from all features.  There 
was little overlap of genes associated with features selected as 
biomarkers for “time awake” and “acute sleep loss” (Figure 7a, 
between individuals; Figure  7b within individuals). The 58 
unique genes associated with biomarkers for predicting “time 
awake, between-subject” included those related to inflamma-
tory responses (NFKB2, NFKBID, CHST2), T-cell development 
(SELK, LRRC8A), ubiquitination (HECTD3, UBE2K), apoptosis 
(PPP1R13B, SORT1, C14orf153 [APOPT1]), RNA splicing/processing 
(BRUNOL6, NOL8, CSDE1, POP1), transcription regulation (DNMT1, 
REST, ZBTB7B, TDG), PI3K signaling (PIK3R3, INPP5F), mTOR sign-
aling (DDIT4), MAPK/PKC/JNK signaling (DUSP22), TNF signaling 
(TNFRSF12A), phosphodiesterase activity (PDE7B), and muscle 
actin binding (PALLD). Eleven of these genes overlapped with 
the panel for “time awake, within-subject” (AF060170, AJ009817, 
BRUNOL6, CRTAP, DUSPSS, GAS2L2, MPP3, POP1, PPP1R13B, REST, 
UBE2K).
The 68 genes associated with classifiers of “acute sleep 
loss, between-subject” included those related to ubiquitination 
(HECTD3, SPOP, ASB6), apoptosis (MAK10, C14orf153 [APOPT1], 
SCRIB), RNA processing (CSDE1, PHAX, GIGYF2, CDC2L1), tran-
scription regulation (TAF2, TAF3, REST, TDG, ELL3, TCF12, ZNF395, 
ZC3H7A, GTF3C2), DNA repair (PDS5B, MCM9), neuron develop-
ment/regulation (NCDN, MPP5, CDC42), phosphodiesterase activ-
ity (PDE7B), muscle actin binding (PALLD), TGF/NFKB signaling 
(FKBP1A, CXXC5), WNT signaling (ZNRF3, WNT6), TNF signaling 
(TNF), MAPK/PI3K signaling (FGR), and mitochondrial electron 
transport (CYCS). Only three genes were also associated with the 
panel for “acute sleep loss, within-subject” (MAK10, PPP1R13B, 
REST).
Thirteen genes were associated with the within-subject 
panels for “time awake” and “acute sleep loss” (Figure 7a) and 
included CRTAP, TDG, PPP1R13B, C14orf153, HECTD3, PALLD, 
MPP3, PDE7B, CSDE1, and REST. Although little genetic overlap, 
there was greater similarity in the GO terms associated with 
all panels for “time awake” and “acute sleep loss” (Figure 7c). 
Top ranked GO terms common to the lists include regulation 
of transcription, apoptotic process, negative regulation of tran-
scription from RNA polymerase II, and signal transduction.
Biomarker panels for chronic sleep loss
a priori knowledge informed panels for chronic sleep loss. Five 
hundred and six features were selected a priori as biomarkers for 
predicting/classifying sleep sufficiency. An interaction network 
analysis of the 506 features showed that there were intercon-
nected nodes related to transcription/translation, RNA process-
ing/transport, chromatin modification/transcription mediation, 
DNA replication/repair, protein ubiquitination and degrad-
ation, and mitochondrial metabolic pathways (Supplementary 
Figure  S3). The node with the largest number of interactions 
(edges) in the network is RIPK4, a serine/threonine kinase that 
interacts with protein kinase C-delta and also activates NFKB. 
Few of these a priori features were selected by elastic net to clas-
sify “chronic sleep insufficiency” and “sleep increase/decrease,” 
with little overlap between the four panels identified. Three 
genes were associated with two of the four lists; STRADB (com-
ponent of complex that activates serine/threonine kinase 11 
and regulates apoptosis via JNK1 signaling), NDUFC1 (subunit of 
mitochondrial NADH dehydrogenase complex 1), and SIAH2 (E3 
ligase involved in protein ubiquitination/degradation).
Panels for chronic sleep loss selected from all features. Given all 
features, elastic net selected nine with which to classify “chronic 
sleep insufficiency” based on sample #1 (or #2). Associated genes 
with known function were related to ubiquitination (SUGT1), 
exocytosis (EXOC6B), translation initiation (EIF2S2), DNA catabo-
lism (DNASE1L2), heat shock protein response (DNAJC9), and Rho 
signaling (ARHGEF6). The 21 features selected to classify “chronic 
sleep insufficiency” based on sample #9 (or #10) were related 
to genes involved in RNA splicing/processing (CDC40, DCP1B, 
NCBP2), transcription regulation (GABPB1, BRMS1L), muscle actin 
binding (TPM3), cell division (POGZ), Golgi protein transport 
(BLZF1, ARFGAP1), acetyltransferase activity (LPCAT1), ubiqui-
tination (SUMO2, SUGT1L1), and proteasome assembly (POMP). 
There was no overlap between the two panels for “chronic sleep 
insufficiency” (Figure 7a).
Thirty-four features were selected for the classification of 
“sleep increase/decrease” using sample #2 (or #3). These were 
related to genes involved in immune/inflammatory response 
(C4B, CCL25), apoptosis (ELMO3), ubiquitination (UBE2F, UBQLN1, 
KLHL24), lysosomal protein degradation (LAMP2), transcription 
regulation (ZNF397), Golgi protein transport (STK25, ERGIC3), 
translation regulation (EEF1A1), endoplasmic reticulum organ-
ization (KIAA1715), WNT signaling (PFTK1), cell proliferation 
(ODC1), mitosis regulation (NUSAP1, ENSA), heat shock protein 
response (HSPA8), and G protein signaling (GPR27). This set of 
genes did not overlap with genes associated with the 62 features 
selected for classifying “sleep increase/decrease” using sample 
#9 (or #10) (Figure 7b). However, at the level of biological func-
tion, the panel for “sleep increase/decrease” using sample #9 
(or #10) overlapped with other panels (e.g. transcription regula-
tion [ZNF395, ZSCAN20, ZNF620, WHSC1, RUNX3, PPHLN1, BATF2], 
muscle actin binding [TPM4], neuron development [SERPINF1, 
S1PR5, NRG1], NFKB signaling [MTDH], JNK signaling [MAGI3], 
heat shock response [HSF2], and G protein signaling [RGS9]), in 
addition to unique functions (e.g., calcium transport [TMEM38B, 
LETM1, CACNB4, CACNA2D2]). One gene, RALGPS1, which regu-
lates Ral protein signaling, was associated with panels for clas-
sifying “sleep increase/decrease” using sample #9 (or #10) and 
predicting “time awake, within-subject” (Figure 7b).
Similarities between biomarker panels for acute and 
chronic sleep loss
There was some overlap in the top ranking GO terms asso-
ciated with the biomarker panels for chronic sleep loss and 
those for acute sleep loss (e.g. transcription, DNA template, 
apoptotic process, signal transduction), but those associ-
ated with chronic sleep loss panels were also enriched for 
terms not found or not highly represented in the acute sleep 
loss panels (e.g. mitotic cell cycle, neutrophil degranulation, 
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mRNA splicing, termination of RNA polymerase II transcrip-
tion, mRNA export from nucleus, translation initiation, regu-
lation of protein stability) (Figure 7c). To make the distinction 
between GO processes associated with good and poor per-
forming biomarker panels, we have highlighted the good per-
forming panels in Figure 7c.
An interaction network of the genes associated with the 
combined panels for acute and chronic sleep loss shows that, 
apart from one gene (ZNF395), there is no overlap, although 
they are connected around some common and also unique bio-
logical functions (Supplementary Figure  S4). Circadian clock 
genes are associated with acute and chronic sleep loss and are 
connected by one of the most connected nodes in the network, 
BTRC, which is the F-box ubiquitin ligase that mediates the deg-
radation of PERIOD (PER) protein. Ubiquitination is common to 
many of the acute sleep loss related panels (e.g. HECTD3, UBE2K), 
and also appears in panels related to chronic sleep loss, albeit 
based on different genes (e.g. UBE2F, SUMO2, SUGT1, UBQLN1). 
The regulation of transcription is also common to both, but 
RNA processing and translation is more restricted to chronic 
sleep loss (e.g. EEF1A1, EIF4B, EIF2S2). Heat shock response pro-
teins (HSPA8, the most connected node, HSF2, and DNAJC9), cal-
cium transport (CACNA2D2, CACNB4) and tropomyosin muscle 
actin binding (TPM3, TPM4) are also only found associated with 
chronic sleep loss. Likewise, TNF signaling (TNF, TNFRSF12A) 
and PI3K signaling (PIK3R3) are restricted to acute sleep loss.
Lack of overlap between circadian markers and 
sleep debt markers
We next investigated whether the mRNA biomarker panels 
for sleep debt status were distinct from the previously iden-
tified mRNA biomarkers for circadian phase [17, 44]. Across 
all approaches (a priori, elastic net applied to UPUS and OPUS 
training sets), we identified 1,195 unique genes/transcripts 
related to biomarkers for sleep-debt related variables. Only 
23 of these (i.e. ~2%) overlap with genes previously reported 
as relevant for assessing circadian phase (data set S3) [17, 44]. 
Even if we exclude the a priori selected genes from this com-
parison because by definition they exclude circadian genes, 
the overlap is only 21 out of 702 genes (data set S3). It is also 
worth noting that approximately one-third of the biomarker 
transcripts for circadian phase did not have circadian expres-
sion profiles (as defined in refs. [18, 21]). The lack of overlap 
between the circadian phase biomarkers and those selected 
from all features for acute and chronic sleep loss is shown in 
Figure 7. Comparison of biomarker panels for different sleep debt related variables. Comparisons made between panels of biomarkers identified when using “all 
features” and “UPUS” as training data to elastic net. (a) Comparison by genes associated with biomarkers that can predict/classify between individuals (i.e. one sam-
ple based). Chronic 1 refers to biomarkers for “chronic sleep insufficiency” identified when using sample #1 (or #2). Chronic 9 refers to biomarkers for “chronic sleep 
insufficiency” identified when using sample #9 (or #10). Circadian phase refers to biomarkers for Circadian phase using one sample as defined in Laing et al. [17]. b) 
Comparison by genes associated with biomarkers that can predict/classify within individuals (i.e. two sample based). Sleep increase 2 refers to biomarkers for “sleep 
increase/decrease” using sample #2 (or #3), sleep increase 9 refers to biomarkers for “sleep increase/decrease” using sample #9 (or #10). Circadian phase refers to bio-
markers for Circadian phase using two samples as defined in Laing et al. [17]. (c) Comparison by associated “top 10 enriched” GO terms, based on the percentage of 
genes associated with the panel that are associated with a given GO term. Highlighted columns are biomarker panels with >70% classification accuracy when applied 
to an independent validation set.
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Figure 7, a and b. This indicates that transcriptional processes 
activated by sleep debt (or sleep homeostasis) are very differ-
ent from those under circadian control. Of the 1,195 only 156 
were identified in more than one independent search (compar-
ing a priori panels with those identified from “all features” by 
elastic net, data set S3). Only 3 of the 156 were also related to 
circadian phase (C17orf55, DDIT4, LDLR). Indeed, transcriptome 
biomarkers previously identified to predict circadian phase 
are more related to blood cell function (immune function) and 
glucocorticoid signaling (inflammatory responses) [17] than to 
the functional processes associated with the sleep loss bio-
markers identified here, which are more generally related to 
cellular stress responses.
Discussion
The results show that biomarker panels derived from the blood 
transcriptome can, on the basis of one blood sample, reliably 
identify whether an individual has skipped one night of sleep, 
even when no baseline data of that participant are available. 
The data also show that when using blood transcriptome 
derived biomarkers, assessment of chronic sleep insufficiency, 
defined as less than 6 hr, is more challenging. However, it may 
be possible to assess changes in sleep sufficiency within an 
individual. Comparison of various validation and feature selec-
tion approaches and several measures of performance supports 
the robustness and validity of the identified biomarker panels. 
Functional annotation of the identified mRNA biomarkers indi-
cates that activation of the cellular stress response is central to 
the consequences of sleep loss.
Performance of mRNA biomarker panels for 
various categories of sleep debt
Acute sleep loss
Performance of mRNA biomarkers for classification of time 
awake in broad categories, that is, wakefulness of more or less 
than 24 hr, or prediction of sleep loss or not, reached respect-
able levels (e.g. 92% for the between-subject assessment of 
“acute sleep loss”). This contrasts with the poor performance of 
mRNA biomarkers for predicting how many hours an individual 
has been awake (i.e. within a range of 7–34  hr), even when a 
within-subject comparison was applied. The latter observa-
tion may imply that the blood transcriptome response to time 
awake is too weak or variable between subjects, or too much 
confounded by circadian variation to make a parametric predic-
tion of hours awake [19]. The latter interpretation is supported 
by a nonlinear time course of the predictor with time awake 
(Figure 3). In the prediction of broader categories this circadian 
confound is reduced (“wakefulness of >24 hr”) or completely 
removed (“acute sleep loss”). This may indeed explain the bet-
ter performance in the classification of broader categories of 
acute sleep loss. Further improvement of parametric predic-
tion may require a combination of biomarkers for assessment 
of circadian phase, which we have shown to be feasible [17], 
with the current panels for “time awake.” Alternatively, other 
machine learning approaches that consider nonlinear relation-
ships between features and variables may be more appropriate. 
Overall, the results demonstrate that the blood transcriptome 
contains information to assess acute sleep loss status even in a 
between-subject assessment, that is, without prior information 
on the blood transcriptome of an individual. Importantly, per-
formance of these predictors was not affected by the prior sleep 
condition. In other words, the performance of the biomarker for 
acute sleep loss was good regardless of whether the total sleep 
deprivation was preceded by a week of sufficient or insufficient 
sleep (Figure 5a, left panel).
Chronic sleep insufficiency
Chronic insufficient sleep in an individual could only be reli-
ably identified on the basis of the blood transcriptome when 
the “sufficient sleep” blood transcriptome information for that 
individual was available. This limitation most likely reflects 
the rather small effects of 1 week of insufficient sleep and the 
rather large between-subject variation in the blood transcrip-
tome [18]. Less than 6 hr of sleep should be considered insuf-
ficient sleep as many epidemiological studies have used 6 hr as 
a cut off below which adverse health outcomes are reported. 
Furthermore, robust changes in sleepiness and neurobehavioral 
performance have been observed under these conditions [2]. It 
may be argued that 1 week does not represent a chronic condi-
tion as far as adverse long-term health outcomes are concerned 
and that longer interventions are needed to identify relevant 
mRNA biomarkers. Furthermore, in the present analysis, we 
contrast insufficient (~5.7 hr assessed by PSG) and sufficient (~ 
8.5  hr assessed by PSG) sleep which was achieved by a 6 and 
10  hr sleep opportunity, respectively. Thus, it may be argued 
that a realistic baseline condition (8 hr sleep opportunity) would 
have provided additional information. Nevertheless, the cur-
rent approaches have identified biomarkers that can be used to 
assess changes in chronic sleep debt status.
Genes associated with panels of biomarkers
Because the identified biomarkers for sleep loss are derived 
from the whole blood-based transcriptome that includes 
mRNA from all blood cell types, a naïve expectation might 
be that transcripts would necessarily be related to blood cell 
functions such as immune responses. However, blood inter-
acts with all tissues and organs and represents a window 
for assessing whole-body function. Thus, gene expression in 
whole-blood can include and respond to a broad range of bio-
logical functions, as we have previously shown [18, 21]. In fact, 
few of the biomarkers that we have identified here are directly 
associated with immune function, although there are recur-
rent links with NFKB inflammatory signaling in the various 
biomarker panels. Indeed, whole blood appears to respond 
to sleep deprivation in ways similar to those observed in 
other tissues. Sleep deprivation and extended wakefulness 
increase energy demands and accumulated oxidative stress. 
Many sleep deprivation studies have found an overall down-
regulation of many genes, presumably as a cellular response 
to limit energy expenditure and reduce associated levels of 
cellular stress [45]. Sleep deprivation has consistently been 
found to induce cellular stress responses and the unfolded 
protein response (UPR) and subsequent endoplasmic retic-
ulum-associated protein degradation (ERAD) in response to 
energy deprivation and oxidative stress [46]. This leads to 
upregulation of gene transcription and protein translation, 
increased heat shock protein chaperone activity in response 
D
ow
nloaded from
 https://academ
ic.oup.com
/sleep/article-abstract/42/1/zsy186/5106128 by U
niversity of Surrey user on 08 August 2019
Laing et al. | 15
to misfolded proteins, higher levels of protein ubiquitination, 
trafficking and degradation, increased cytokine-mediated 
inflammatory responses, and ultimately cell injury and apop-
tosis (e.g. Naidoo [47]). Many of the biomarkers that we have 
identified for sleep loss in this study are directly related to 
these cellular responses, including markers for specific mito-
chondrial metabolic pathways.
Short sleep duration in adults has previously been associated 
with biomarkers for inflammation [48, 49], including TNF which 
was identified as a biomarker for acute sleep loss in the cur-
rent study. The misfolded protein response heat shock protein 
HSP70 is upregulated in the rat brain following sleep deprivation 
[50] and also in patients with sleep apnea [51]. HSPA8 is a mem-
ber of the HSP70 family of proteins and was identified as a bio-
marker for chronic sleep loss in this study. DNA damage induced 
by cellular stress is also increased after partial and total sleep 
loss in rats [52] and genes for several DNA repair proteins were 
found in biomarker panels for both acute and chronic sleep loss. 
Mitochondrial enzymes have been shown to be biomarkers in 
rats for sleep deprivation in response to higher cellular energy 
demands required during prolonged wakefulness [53]. In the 
present study, we identified three NADH ubiquinone oxidore-
ductase subunits (NDUFC1, NDUFS1, NDUF89) and a succinate 
dehydrogenase subunit (SDHD) as biomarkers for chronic sleep 
loss, and cytochrome C (CYCS) as a biomarker for acute sleep 
loss. There is also a growing literature showing that sleep depri-
vation impairs adult neurogenesis (e.g. hippocampal-associated 
learning [54]) and several biomarkers for sleep loss were associ-
ated with neuronal development and regulation in this study.
Amylase has previously been identified as a highly correlated 
biomarker for sleep drive in drosophila, and saliva enzyme activ-
ity and RNA abundance also correlated with sleep deprivation in 
humans [13]. Mannosidase is structurally very similar to amyl-
ase and both degrade polysaccharides [55]. The list of 506 a priori 
features for “sleep sufficiency” was enriched for the GO molecu-
lar function “mannosidase activity” (MAN2A1, MAN2A2, MAN2B2, 
KIAA2018). Amylase gene expression in humans is specific to sal-
iva and the pancreas and it could be that mannosidase activity 
in human blood represents an equivalent blood-based biomarker 
for chronic sleep loss. Diacylglycerol (DAG 36:3) has also been 
identified as a marker for sleep debt in both rats and humans [14]. 
It is worth noting that while we did not identify any DAG-related 
transcripts (e.g. DAG kinase or lipase) in our biomarker panels, 
it is known that DAG can be converted to phosphatidic acid and 
thus regulate mTOR signaling via PI3K pathways [56, 57], both of 
which we see represented in our sleep loss biomarker panels.
Adenosine is a known mediator of sleep-promoting effects 
of wake and a potential biomarker for prolonged wakefulness 
[58], but we do not see any adenosine-related transcripts in our 
panels for acute or chronic sleep loss. We do however identify 
the GABA type A receptor (GARBRP) and a GABA type A recep-
tor associated protein (GABARAPL2) as potential biomarkers for 
chronic sleep loss. GABAergic neurons in the brain regulate sleep 
[59] and numbers of GABA receptors in those neurons change in 
response to sleep deprivation [60].
Finally, it should be noted that many of the genes associated 
with identified biomarkers have a role in muscle and cardiac 
function, with links to cardiovascular disease (e.g. SELK protects 
cardiomyocytes from stress, INPPSF modulates cardiac response 
to stress, TAF3 regulates myocyte differentiation, THBS4 regu-
lates myocardial function, ANK3 regulates cardiac muscle 
contraction, and MAK10 regulates smooth muscle proliferation). 
Short sleep has been shown to be associated with cardiovas-
cular disease [61]. Also, because many transcripts have roles in 
transcription/translation and cell proliferation/apoptosis there 
are links with a range of different cancers, which may be related 
to sleep loss and increased risk of cancer observed in shift work-
ers [3]. REST also appears in several of the acute sleep loss lists 
and, in addition to being a suppressor of neuronal genes in non-
neuronal cells, protects neurons from oxidative stress and amyl-
oid β-protein toxicity [62]. REST is down-regulated in Alzheimer’s 
and its expression levels correlate with longevity [62]. Thus, in 
addition to representing robust and reliable biomarkers for sleep 
status, the identified RNA abundance features may also be asso-
ciated with the long-term adverse effects of sleep disruption.
Specificity of identified blood mRNA 
biomarkers of sleep debt and practicality 
of use.
Sleep, circadian processes and external (i.e. lifestyle and envi-
ronmental) factors all interact. In our protocol, the effects of 
external factors were minimized as we assessed a cohort of 
healthy individuals of similar age, under clinically controlled 
conditions. However, samples collected across the constant 
routine describe changes in the transcriptome in response to 
sleep debt that also include circadian modulation. We thus con-
sidered the timing of samples, focused on those comparisons 
that removed the confounding effects of circadian processes, to 
identify specific biomarkers of sleep debt.
The usefulness of these biomarkers in the real world will 
depend on various factors. A concern is that these biomarkers 
are not just affected by sleep debt parameters but also health 
status which is likely to affect immune function. However, 
when comparing all panels, it is encouraging to note that not 
many of the identified biomarkers are associated with immune 
responses. In fact, the majority of the biomarkers are associ-
ated with more generalized cellular functions, and in particu-
lar, the regulation of transcription and translation, including 
common signaling pathways such as WNT, mTOR, and PI3K. 
Other common themes included protein transport/degradation 
and ubiquitination, apoptosis, mitosis and cell proliferation, 
neuronal development and function, and aspects of skeletal 
and cardiac muscle function. Hence, as the panel of biomark-
ers was associated with multiple processes, we expect their 
predictions/classifications to be more robust than the single 
molecules reported to date [13, 14]. Similarly, other biomarkers 
which associate with lipid metabolism, glucose transport, and 
insulin responses may also be sensitive to individual differ-
ences in feeding and fasting and we did identify features that 
are associated with these responses. In particular, elements of 
the PI3K signaling pathway that also regulates insulin signal-
ing were common to many of the panels for the classification 
of “acute sleep loss.” Determining a final panel of biomarkers 
(and associated prediction/classification model) for real world 
application will therefore require further assessment of the 
population, including different conditions to those assessed 
in our protocol, and the acceptable trade-off between sensi-
tivity and specificity to be defined. The blood transcriptome 
and the response to sleep loss varies with age [63]. Therefore, it 
will also be important to investigate the performance of these 
mRNA biomarkers in other age groups.
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Methodological considerations
We used a multitude of approaches related to feature selection, 
creation of training and validation sets, validation methods and 
used various indices of biomarker performance, with the aim 
to create transparency about the robustness of our results and 
their dependency on the applied methods.
Use of a priori knowledge versus prefiltering versus unbiased 
approaches. Identifying panels of biomarkers for “time awake” 
and “acute sleep loss” between individuals (no baseline correc-
tion), it was clear that there is an advantage in using “all features” 
as input (6%–15% higher performance for UPUS data). However, 
this advantage was reduced when considering the individual 
(“acute sleep loss, within-subject”). This we expect to be due to 
our approach to selecting the a priori selected features, which rests 
on the within participant analysis we conducted and reported in 
Möller-Levet et al. [18]. Conversely, for variables related to sleep 
sufficiency, we found prior knowledge to be beneficial. While this 
is likely due to the selection criteria applied, in that the entire 
time series and data set were considered in our a priori selection, 
our work highlights the need to assess different sets of input fea-
tures, with and without filtering, for biomarker discovery.
Creating training and validation sets: UPUS versus  OPUS. The 
available data include many samples (496) but few unique indi-
viduals (36). Such data pose a challenge for machine learning. 
Thus, we used the “gold standard” approach to create independ-
ent training and validation sets that comprise samples from dis-
tinct participants (UPUS). The disadvantage to this approach is that 
the number of participants to “learn” from is reduced and may not 
be representative of the population. We therefore investigated an 
alternative approach (OPUS) that increased the number of individ-
uals within a training set. Due to the differences in data set struc-
tures (differing number of features, participants) Elastic net applied 
to each training set identified different panels of biomarkers, with 
varying degrees of overlap (data set S2). We would expect these dif-
ferences to be reconciled with the availability of a greater number 
of samples/participants. Nevertheless, to further understanding 
of the molecular mechanisms associated with sleep debt the bio-
markers identified by different approaches will be of interest.
Validation methods. The entire data set consists of many highly 
correlated samples, where samples from the same individual 
look most similar to each other due to the “trait-like” charac-
teristics of the human blood transcriptome [17, 27]. If not han-
dled correctly this similarity can lead to optimistic measures 
of performance, even though our algorithms are “blind” to the 
participants from which transcriptomes originated. Thus, we 
used different approaches to validate performance. Comparing 
LOSO-CV and IV performance of each search revealed, in gen-
eral, similar values. This implies that the procedures imple-
mented adequately prevented overfitting and controlled for 
optimism in our assessment of performance. Several features of 
our workflow will have aided this; two different cross-validation 
strategies were employed, meaning that our “tuning” of hyper-
parameters and assessment of performance were independent 
[25], the 10-fold cross-validation was repeated a large number of 
times [26], and we considered the “trait-like” behavior of -ome 
samples [27] and performed LOSO-CV. Our use of different met-
rics to assess classification performance was necessary as each 
approach and hence validation set was different. Our use of the 
unbiased (to size of classes) metric of MCC enabled the compari-
son of each panel despite differences in class sizes. Reporting 
sensitivity and specificity is relevant to the selection of a panel 
for future real-world applications.
Weaknesses and strengths of the current 
approach
The results are based on carefully controlled laboratory studies in 
healthy young volunteers. This is a weakness because it obviously 
leaves open the question of generalizability to the broader popu-
lation in real life situations. It is also a strength because the to-be-
predicted sleep debt parameters were carefully quantified. Sleep 
debt parameters were manipulated within a physiological range. 
It can be argued that more extreme manipulations, for example, 
72 hr awake or sleep restriction to 4 hr or less, would have iden-
tified more specific biomarkers. On the other hand, biomarkers 
identified in more extreme protocols may not be relevant to most 
real-world situations, in which very few people will be awake 
for 72 hr or sleep less than 4 hr for a week. Another weakness 
relates to the small sample size. The results from the IV indicate 
the identified biomarkers are able to generalize to independent 
samples and are therefore unlikely to reflect a response unique 
to a particular group of participants. However, without further 
validation, we are unable to assess the robustness and inter- and 
intraindividual variability of the selected markers. A strength of 
the current analyses is that we have quantified the ability of a 
panel of biomarkers derived from one (or two) samples to predict 
an individual’s sleep debt status rather than simply listing fea-
tures that on average change with sleep debt parameters.
Concluding remarks
Here, we present the first multivariate search and validation of 
panels of human blood transcriptome biomarkers for sleep debt 
related variables. Though unable to identify a panel of biomark-
ers capable of accurately predicting “time awake” (maximum R2 
across methods of 0.29), we did identify biomarkers able to clas-
sify an individual as having “acute sleep loss” with 92% accuracy. 
Accurately discriminating between individuals who have experi-
enced insufficient sleep (5.75 hr) from those who have had suffi-
cient sleep (8.5 hr) we consider to still be a challenge (maximum 
accuracy achieved here of 57%). However, within an individual, it 
is possible to identify an increase/decrease in sleep sufficiency 
with 89% accuracy, even though the average difference in sleep 
duration was relatively small (2.8 hr). Many of the biomarkers for 
sleep loss that we have identified are related to cellular responses 
to stress known to be induced by sleep deprivation and include 
previously identified single feature biomarkers.
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